Author correction to ‘Actively priming autophagic cell death with novel transferrin receptor-targeted nanomedicine for synergistic chemotherapy against breast cancer’ [Acta Pharmaceutica Sinica B 2019; 9(5):1061–1077]

• Dong Mei,
• Binlong Chen,
• Bing He,
• Haibin Liu,
• Zhiqiang Lin,
• Jialiang Lin,
• Xiaoyan Zhang,
• Ning Sun,
• Libo Zhao,
• Xiaoling Wang,
• Qiang Zhang

Affiliations

Dong Mei

Clinical Research Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China; Key Laboratory of Molecular Pharmaceutics, New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China

Binlong Chen

Key Laboratory of Molecular Pharmaceutics, New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China

Bing He

Key Laboratory of Molecular Pharmaceutics, New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China

Haibin Liu

Department of General Surgery, China–Japan Friendship Hospital, Beijing 100029, China

Zhiqiang Lin

Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China

Jialiang Lin

Key Laboratory of Molecular Pharmaceutics, New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China

Xiaoyan Zhang

Clinical Research Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China

Ning Sun

Clinical Research Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China

Libo Zhao

Clinical Research Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China

Xiaoling Wang

Clinical Research Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China; Corresponding authors.

Qiang Zhang

Key Laboratory of Molecular Pharmaceutics, New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; Corresponding authors.